Journal
JACC-CARDIOVASCULAR INTERVENTIONS
Volume 7, Issue 8, Pages 827-839Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jcin.2014.05.008
Keywords
drug-coated stents; drug-coated balloons; peripheral artery disease; review
Categories
Funding
- Amarin
- AstraZeneca
- Bristol-Myers Squibb
- Eisai
- Ethicon
- Medtronic
- Roche
- Sanofi-Aventis
- Medicines Company
- Guerbet
- Boston Scientific
Ask authors/readers for more resources
Endovascular intervention has become a well-recognized treatment modality for peripheral artery disease; however, mid- and long-term outcomes have been plagued by limited durability. Plain balloon angioplasty and bare-metal stents have historically suffered from high restenosis rates leading to the need for frequent repeat revascularization procedures. The innovation of locally administered, drug-delivering balloons and stents has been a direct result of technological innovations directed toward prevention and treatment of this limitation. Over the last 5 years, numerous clinical trials investigating the use of drug-coated stents and drug-coated balloons indicate a significant improvement in endovascular treatment durability and outcomes. This review provides an up-to-date assessment of the current evidence for the use of drug-coated stents and drug-coated balloons in the treatment of femoropopliteal and infrapopliteal peripheral artery disease. Additionally, it provides an overview of the development of this technology, highlights landmark ongoing and completed clinical trials, examines evidence to support the use of drug-coated technologies in combination with other modalities, and examines promising new technological developments. Last, it summarizes the challenges and safety concerns that have delayed U.S. Food and Drug Administration approval of these devices. (C) 2014 by the American College of Cardiology Foundation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available